1
|
Billich A, Billich S, Rosenwirth B. Assay Systems for HIV-1 Proteinase and Their Use for Evaluation of Inhibitors. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029100200201] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- A. Billich
- Sandoz Forschungsinstitut GmbH, Department of AntiRetroviral Therapy, Brunnerstr. 59, A-1235 Vienna, Austria
| | - S. Billich
- Sandoz Forschungsinstitut GmbH, Department of AntiRetroviral Therapy, Brunnerstr. 59, A-1235 Vienna, Austria
| | - B. Rosenwirth
- Sandoz Forschungsinstitut GmbH, Department of AntiRetroviral Therapy, Brunnerstr. 59, A-1235 Vienna, Austria
| |
Collapse
|
2
|
Matúz K, Mótyán J, Li M, Wlodawer A, Tőzsér J. Inhibition of XMRV and HIV-1 proteases by pepstatin A and acetyl-pepstatin. FEBS J 2012; 279:3276-86. [PMID: 22804908 PMCID: PMC6290463 DOI: 10.1111/j.1742-4658.2012.08714.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The kinetic properties of two classical inhibitors of aspartic proteases (PRs), pepstatin A and acetyl-pepstatin, were compared in their interactions with HIV-1 and xenotropic murine leukemia virus related virus (XMRV) PRs. Both compounds are substantially weaker inhibitors of XMRV PR than of HIV-1 PR. Previous kinetic and structural studies characterized HIV-1 PR-acetyl-pepstatin and XMRV PR-pepstatin A complexes and suggested dramatically different binding modes. Interaction energies were calculated for the possible binding modes and suggested a strong preference for the one-inhibitor binding mode for HIV-1 PR-acetyl-pepstatin and the two-inhibitor binding mode for XMRV PR-pepstatin A interactions. Comparison of the molecular models suggested that in the case of XMRV PR the relatively unfavorable interactions at S3' and the favorable interactions at S4 and S4' sites with the statine residues may shift the ground state binding towards the two-inhibitor binding mode, whereas the single molecule ground state binding of statines to the HIV-1 PR appear to be more favorable. The preferred single molecular binding to HIV-1 PR allows the formation of the transition state complex, represented by substantially better binding constants. Intriguingly, the crystal structure of the complex of acetyl-pepstatin with XMRV PR has shown a mixed type of binding: the unusual binding mode of two molecules of the inhibitor to the enzyme, in a mode very similar to the previously determined complex with pepstatin A, together with the classical binding mode found for HIV-1 PR. The structure is thus in good agreement with the very similar interaction energies calculated for the two types of binding.
Collapse
Affiliation(s)
- Krisztina Matúz
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - János Mótyán
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - Mi Li
- Protein Structure Section, Macromolecular Crystallography Laboratory, National Cancer Institute - Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
- Basic Research Program, SAIC-Frederick, Frederick, MD 21702, USA
| | - Alexander Wlodawer
- Protein Structure Section, Macromolecular Crystallography Laboratory, National Cancer Institute - Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
| | - József Tőzsér
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| |
Collapse
|
3
|
Szecsi PB. The aspartic proteases. Scandinavian Journal of Clinical and Laboratory Investigation 2011. [DOI: 10.1080/00365519209104650] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp. Exp Parasitol 2010; 126:557-63. [DOI: 10.1016/j.exppara.2010.06.002] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2009] [Revised: 05/06/2010] [Accepted: 06/01/2010] [Indexed: 11/21/2022]
|
5
|
Sherman W, Tidor B. Novel method for probing the specificity binding profile of ligands: applications to HIV protease. Chem Biol Drug Des 2008; 71:387-407. [PMID: 18384529 DOI: 10.1111/j.1747-0285.2008.00659.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
A detailed understanding of factors influencing the binding specificity of a ligand to a set of desirable targets and undesirable decoys is a key step in the design of potent and selective therapeutics. We have developed a general method for optimizing binding specificity in ligand-receptor complexes based on the theory of electrostatic charge optimization. This methodology can be used to tune the binding of a ligand to a panel of potential targets and decoys, along the continuum from narrow binding to only one partner to broad binding to the entire panel. Using HIV-1 protease as a model system, we probe specificity in three distinct ways. First, we probe interactions that could make the promiscuous protease inhibitor pepstatin more selective toward HIV-1 protease. Next, we study clinically approved HIV-1 protease inhibitors and probe ways to broaden the binding profiles toward both wild-type HIV-1 protease and drug-resistant mutants. Finally, we study a conformational ensemble of wild-type HIV-1 protease to 'design in' broad specificity to known drugs before resistance mutations arise. The results from this conformational ensemble were similar to those from the drug-resistant ensemble, suggesting the use of a conformational wild-type ensemble as a tool to develop escape-mutant-resistant inhibitors.
Collapse
Affiliation(s)
- Woody Sherman
- Schrodinger, Inc., 120 West 45th Street, New York, NY 10036, USADepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139-4307, USAComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA 02139-4307, USADepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139-4307, USADepartment of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA 02139-4307, USA
| | - Bruce Tidor
- Schrodinger, Inc., 120 West 45th Street, New York, NY 10036, USADepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139-4307, USAComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA 02139-4307, USADepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139-4307, USADepartment of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA 02139-4307, USA
| |
Collapse
|
6
|
Valdivieso E, Dagger F, Rascón A. Leishmania mexicana: Identification and characterization of an aspartyl proteinase activity. Exp Parasitol 2007; 116:77-82. [PMID: 17126324 DOI: 10.1016/j.exppara.2006.10.006] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2006] [Revised: 10/09/2006] [Accepted: 10/12/2006] [Indexed: 11/25/2022]
Abstract
An aspartyl proteinase activity was detected in the soluble fraction (SF) of Leishmania mexicana promastigotes by the use of the synthetic substrate benzoyl-Arg-Gly-Phe-Phe-Leu-4-methoxy-beta-naphthylamide selective for Cathepsin D like aspartyl-proteinases. This peptide was hydrolyzed with an apparent K(m) of 2.3+/-0.3 microM. The classic inhibitor of aspartyl-proteinases, diazo-acetyl-norleucinemethylester (DAN) inhibited the proteolytic activity with an IC(50) of 400 microM. The soluble fraction degraded (in absence of thiol groups) human fibrinogen with a specific activity of 533 U/mg protein. When tested for the ability to inhibit the "in vitro" proliferation of L. mexicana promastigotes, DAN showed concentration dependent anti-proliferative effects with a LD(50) of 466 microM at 48 h, with a significant fall in this value to 22 microM after 72 h. This is the first characterization of an aspartyl-proteinase activity in Leishmania, calling for further studies directed towards the physiologic role of these enzymes in the parasite. The anti-proliferative effect of its inhibition makes this enzyme a putative new target for the development of leishmanicidal drugs.
Collapse
Affiliation(s)
- Elizabeth Valdivieso
- Laboratorio de Biología Celular de Parásitos, Instituto de Biología Experimental, Facultad de Ciencias, Universidad Central de Venezuela, Apartado Postal 47069, Caracas 1041-A, Venezuela.
| | | | | |
Collapse
|
7
|
Bravo P, Bruché L, Pesenti C, Viani F, Volonterio A, Zanda M. Solution and solid-phase synthesis of trifluoromethyl peptides and mimetics. J Fluor Chem 2001. [DOI: 10.1016/s0022-1139(01)00485-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Pesenti C, Arnone A, Bellosta S, Bravo P, Canavesi M, Corradi E, Frigerio M, Meille SV, Monetti M, Panzeri W, Viani F, Venturini R, Zanda M. Total synthesis of a pepstatin analog incorporating two trifluoromethyl hydroxymethylene isosteres (Tfm-GABOB) and evaluation of Tfm-GABOB containing peptides as inhibitors of HIV-1 protease and MMP-9. Tetrahedron 2001. [DOI: 10.1016/s0040-4020(01)00543-9] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Babé LM, Linnevers CJ, Schmidt BF. Production of active mammalian and viral proteases in bacterial expression systems. Biotechnol Genet Eng Rev 2001; 17:213-52. [PMID: 11255667 DOI: 10.1080/02648725.2000.10647993] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- L M Babé
- Axys Pharmaceuticals Inc., 180 Kimball Way, South San Francisco, CA 94080, USA.
| | | | | |
Collapse
|
10
|
Cherry E, Liang C, Rong L, Quan Y, Inouye P, Li X, Morin N, Kotler M, Wainberg MA. Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins. J Mol Biol 1998; 284:43-56. [PMID: 9811541 DOI: 10.1006/jmbi.1998.1968] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We have selectively mutagenized specific residues at the junction between the protease (PR) and reverse transcriptase (RT) genes of human immunodeficiency virus type 1 (HIV-1) to study the effects of PR-RT fusion proteins in the context of a full-length, infectious proviral construct. Mutant viruses derived from COS-7 cells transfected with this construct were analyzed in regard to each of viral replication, maturation, and infectivity. Immunoblot analysis revealed that the mutation prevented cleavage between the PR and RT proteins and that both existed as a PR-RT fusion protein in each of cellular and viral lysates. Interestingly, intracellular PR that existed within the PR-RT fusion protein remained functionally active, whereby HIV-1 precursor proteins were processed efficiently. Furthermore, the RT component of the fusion protein also retained its enzymatic activity as shown in RT assays. Electron microscopy revealed that the mutant viruses containing the PR-RT fusion protein possessed wild-type morphology. These viruses also displayed wild-type sensitivities to inhibitors of each of the HIV-1 PR and RT activities. However, viruses containing the PR-RT fusion protein were 20 times less infectious than wild-type viruses. This defect was further pronounced when mutated Gag-Pol proteins were overexpressed as a consequence of an additional mutation that interfered with frameshifting. Thus, unlike cleavage site mutations at the N terminus of PR, a cleavage site mutation between PR and RT did not affect the enzymatic activities of either PR or RT and viruses containing PR-RT fusion proteins were viable.
Collapse
Affiliation(s)
- E Cherry
- McGill University AIDS Centre, Lady Davis Institute-Jewish General Hospital, Montreal, H3T 1E2, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Dergousova NI, Volynskaya AM, Rumsh LD. HIV-I protease. Cloning, expression, and purification. Appl Biochem Biotechnol 1996; 61:97-107. [PMID: 9100348 DOI: 10.1007/bf02785692] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
A new method for obtaining HIV-I protease was suggested. Fusion proteins composed of the N-terminal fragment of human gamma-interferon and HIV-I protease connected with (Asp)4Lys (protein I) or Asp-Pro (protein II) linkers were expressed in Escherichia coli cells. The fusion proteins were produced as insoluble inclusion bodies in the 20% yield of total cell protein. Protein I was cleaved by enterokinase. The solubility of protein I was increased by treating with Na-sulfite/Na-tetrathionate under denaturing conditions. Optimal conditions for efficient acidic hydrolysis of protein II at Asp-Pro bond were found. The hydrolysis products were separated by reversed-phase FPLC. The amount of tryptophan and cysteine residues in the enzyme obtained was estimated. The activity of HIV-I protease was determined using the chromogenic peptide. AlaArgVal NleNphGluAlaNleNH2 and a high-mol-wt substrate consisting of beta-galactosidase and a fragment of gag proteins, including p17-p24 processing site.
Collapse
Affiliation(s)
- N I Dergousova
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
| | | | | |
Collapse
|
12
|
Yu SL, Wang N, Liou CY, Syu WJ. Assay of HIV-1 protease activity by use of crude preparations of enzyme and biotinylated substrate. J Virol Methods 1995; 53:63-73. [PMID: 7635927 DOI: 10.1016/0166-0934(94)00177-i] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
An enzyme immunoassay was developed for monitoring protease reactions of human immunodeficiency virus (HIV). The protease and its substrate, the gag precursor, were generated separately in Escherichia coli. The HIV-1 protease was generated with a glutathione-S-transferase expression system and the gag substrate, named Pin17/24, was prepared with a PinPoint expression system. Pin17/24 consists of an N-terminal peptide, which is biotinylated in E. coli, fused with a C-terminal peptide that contains a protease cleavage site flanked by p17 and p24 segments. Through its biotin in the N-terminal region, Pin17/24 bound to ELISA plates coated with avidin, whereas through its C-terminal region, the same molecule of Pin17/24 could be recognized by an anti-p24 monoclonal antibody. When the protease was added to Pin17/24, the p24 fragment was released from the biotinylated fusion protein and could no longer be retained on the avidin plates, and as a result, binding of the anti-p24 monoclonal antibody decreased. The binding was specific and the reaction was inhibited by a known HIV protease inhibitor. Due to the specific interactions between avidin and biotin, monoclonal antibody and antigen, and the HIV protease and the gag substrate, crude preparations of these reagents can be used readily in the assay. The simplicity and feasibility of this method should be useful for simultaneous monitoring of many enzyme reactions, particularly for screening possible HIV protease inhibitors.
Collapse
Affiliation(s)
- S L Yu
- Graduate Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan, ROC
| | | | | | | |
Collapse
|
13
|
Viani S, Condom R, Frogier PRT, Guedj R. Peptides Containing 2-, 3- or 4-Fluorophenylalanine or 2,2- or 3,3-Difluorophenylalanine as Potential Inhibitors of HIV Protease. Antivir Chem Chemother 1995. [DOI: 10.1177/095632029500600108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
A series of peptide mimetic substrates of the HIV-1 protease, corresponding substantially to the amino acid sequence of the Tyr-Pro cleavage site contained in the gag polyprotein, in which the tyrosine amino acid of the scissile bond was replaced by 2-, 3- or 4-fluorophenylalanine or 2,2- or 3,3-difluorophenylalanine, has been developed. The synthesis of these compounds and the results of inhibition studies are described.
Collapse
Affiliation(s)
- S. Viani
- Laboratoire de Chimie Bio-Organique, Université de Nice-Sophia Antipolis, Faculté des Sciences, BP N°71, F-06108 Nice Cedex 2, France
| | - R. Condom
- Laboratoire de Chimie Bio-Organique, Université de Nice-Sophia Antipolis, Faculté des Sciences, BP N°71, F-06108 Nice Cedex 2, France
| | - P. R. T. Frogier
- Laboratoire de Chimie Bio-Organique, Université de Nice-Sophia Antipolis, Faculté des Sciences, BP N°71, F-06108 Nice Cedex 2, France
| | - R. Guedj
- Laboratoire de Chimie Bio-Organique, Université de Nice-Sophia Antipolis, Faculté des Sciences, BP N°71, F-06108 Nice Cedex 2, France
| |
Collapse
|
14
|
Goobar-Larsson L, Luukkonen BG, Unge T, Schwartz S, Utter G, Strandberg B, Oberg B. Enhancement of HIV-1 proteinase activity by HIV-1 reverse transcriptase. Virology 1995; 206:387-94. [PMID: 7530393 DOI: 10.1016/s0042-6822(95)80054-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
HIV-1 reverse transcriptase (RT) was found to increase the activity of HIV-1 proteinase in vitro and in eukaryotic cells. The effect of RT on proteinase activity was dose-dependent and independent of pH or salt concentration. The cleavage of sequences corresponding to all the naturally occurring cleavage sites that could be tested in vitro was enhanced. The effect of RT on cleavage was greatest at the cleavage site between RT and integrase. The enhancement of viral proteinase activity by the virus RT may contribute to regulation of the order and/or efficiency of cleavage at different sites during virus replication and maturation.
Collapse
Affiliation(s)
- L Goobar-Larsson
- Microbiology and Tumorbiology Center (MTC), Karolinska Institute, Stockholm, Sweden
| | | | | | | | | | | | | |
Collapse
|
15
|
Martin JA, Redshaw S, Thomas GJ. Inhibitors of HIV proteinase. PROGRESS IN MEDICINAL CHEMISTRY 1995; 32:239-87. [PMID: 8577919 DOI: 10.1016/s0079-6468(08)70455-7] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- J A Martin
- Roche Products Ltd., Welwyn Garden City, Herts, UK
| | | | | |
Collapse
|
16
|
Munoz B, Giam CZ, Wong CH. Alpha-ketoamide Phe-Pro isostere as a new core structure for the inhibition of HIV protease. Bioorg Med Chem 1994; 2:1085-90. [PMID: 7773625 DOI: 10.1016/s0968-0896(00)82058-1] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Studies on the inhibition of HIV-1 protease utilizing a core isostere with replacement of the scissle bond for an alpha-amino-ketone have resulted in the development of an alpha-keto-amide isosteric replacement of the Phe-Pro scissle amide bond. The simple dipeptide isostere was shown to be a promising new core structure for the development of the enzyme inhibitors. The Ki of this core structure was determined to be 6 microM, compared to 230 microM and > 50 microM for the corresponding phosphinic acid and hydroxyethylamine isosteres.
Collapse
Affiliation(s)
- B Munoz
- Department of Chemistry, Scripps Research Institute, La Jolla, CA 92037, USA
| | | | | |
Collapse
|
17
|
Marczinovits I, Molnár J, Patthy A. Staphylococcal protein A is a novel heterologous substrate for the HIV-1 protease. J Biotechnol 1994; 37:79-83. [PMID: 7765414 DOI: 10.1016/0168-1656(94)90205-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Upon in vitro processing of the recombinant HIV-1/gag p24 protein, expressed in Escherichia coli as a fusion protein, by HIV-1 protease, a cleavage site within the staphylococcal protein A fusion partner was found. N-terminal sequencing of the protein A fragments showed that HIV-1 protease cleavage occurred between phenylalanine-235 and tyrosine-236 within the sequence Gln-Asn-Ala-Phe/Tyr-Glu-Ile-Leu (QNAF/YEIL) in the IgG-binding domain C of the protein A encoded by the pRIT2T fusion gene vector (Pharmacia). Results presented here have proven that the protease-sensitive site is viable in vitro on the protein A alone and other chimeric protein, protein A/beta-galactosidase. A possible significance of this phenomenon in biotechnology work is discussed.
Collapse
Affiliation(s)
- I Marczinovits
- Institute of Microbiology, Albert Szent-Györgyi Medical University, Szeged, Hungary
| | | | | |
Collapse
|
18
|
Polgár L, Szeltner Z, Boros I. Substrate-dependent mechanisms in the catalysis of human immunodeficiency virus protease. Biochemistry 1994; 33:9351-7. [PMID: 8049236 DOI: 10.1021/bi00197a040] [Citation(s) in RCA: 55] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The most preferred residue in the substrates of human immunodeficiency virus (HIV-1) protease is glutamic acid in the P2' position. The catalytic importance of this charged residue has been studied to obtain a detailed insight into the mechanism of action, which will promote drug design to combat the virus. To this end, we have synthesized Lys-Ala-Arg-Val-Leu*Phe(NO2)-Glu-Ala-Nle (substrate E) and its counterpart containing the neutral Gln (substrate Q) in place of Glu. Kinetic analyses have shown that the specificity rate constants (kcat/Km) display bell-shaped pH dependencies for both substrates, but the pH-independent limiting value is 35-40-fold higher with substrate E than with substrate Q. In contrast to the pH-rate profiles of kcat/Km, there is a striking difference between the pH dependencies of Km and kcat for the two substrates. This indicates different ground state and transition state stabilizations in the two reactions. Solvent kinetic deuterium isotope effects show that the rate-limiting step for the hydrolysis of substrate E is a chemical step coupled with proton transfer whereas with substrate Q it is a physical step, presumably a conformational change. Accordingly, the charged residue in P2' alters the rate-limiting step and the nature of the enzyme-substrate complex, resulting in different mechanisms for the two substrates.
Collapse
Affiliation(s)
- L Polgár
- Institute of Enzymology, Hungarian Academy of Sciences, Budapest
| | | | | |
Collapse
|
19
|
Affiliation(s)
- J Stebbins
- Department of Molecular Genetics, Smihkline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
| | | |
Collapse
|
20
|
Marczinovits I, Boros I, el Jarrah F, Füst G, Molnár J. Expression in Escherichia coli and in vitro processing of HIV-1 p24 fusion protein. J Biotechnol 1993; 31:225-32. [PMID: 7764303 DOI: 10.1016/0168-1656(93)90163-h] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Recombinant HIV-1 p24/p25 gag proteins were obtained from Escherichia coli using a cleavable fusion strategy. The fusion protein contains 280 amino acid residues of staphylococcal Protein A and 317 amino acid residues of p24/p25 flanking with the recognition/cleavage sequences for HIV protease. Fusion protein expressed under the control of lambda phage promoter PR was purified by IgG-Sepharose affinity chromatography. The p24/p25 part of the fusion protein was released by recombinant HIV protease in vitro. After a second IgG-Sepharose affinity chromatography, the purified p24/p25 proteins were obtained in milligram quantities. The HIV-1 p24/p25 protein displayed antigenicity similar to those of native counterparts confirmed by Western blot assays and the Abbott antigen test.
Collapse
Affiliation(s)
- I Marczinovits
- Institute of Microbiology, Albert Szent-Györgyi Medical University, Szeged, Hungary
| | | | | | | | | |
Collapse
|
21
|
Leuthardt A, Roesel JL. Cloning, expression and purification of a recombinant poly-histidine-linked HIV-1 protease. FEBS Lett 1993; 326:275-80. [PMID: 8325379 DOI: 10.1016/0014-5793(93)81807-c] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The gene coding for the HIV-1 protease was cloned in an Escherichia coli expression vector adding three-histidine codons to the amino and carboxy terminus of the protease sequence. Expression of the protease from this construct led to the accumulation of high amounts of insoluble histidine-linked protease entrapped in inclusion bodies. The histidine-linked protease could be efficiently released from purified inclusion bodies with 6 M guanidine hydrochloride and further purified by metal chelate affinity chromatography. The refolded protease cleaved synthetic peptide substrates and the viral polyprotein p55 with the same specificity as the wild type protease. It displays a specific activity of 4.4 mumol/min/mg.
Collapse
Affiliation(s)
- A Leuthardt
- Ciba-Geigy Ltd., Oncology and Virology Research Department, Basel, Switzerland
| | | |
Collapse
|
22
|
Rangwala SH, Finn RF, Smith CE, Berberich SA, Salsgiver WJ, Stallings WC, Glover GI, Olins PO. High-level production of active HIV-1 protease in Escherichia coli. Gene 1992; 122:263-9. [PMID: 1487142 DOI: 10.1016/0378-1119(92)90214-a] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
High levels of active HIV-1 protease (PR) were produced in Escherichia coli, amounting to 8-10% of total cell protein. High production levels were achieved by altering the following parameters: (1) codon preference of the coding region, (2) A+T-richness at the 5' end of the coding region, and (3) promoter. To circumvent the toxicity of HIV-1 PR in E. coli, the gene was expressed as a fusion protein with two different proteolytic autocleavage sequences. In both the cases, the fusion protein could be cleaved in vivo to give an active molecule with the native sequence at the N terminus.
Collapse
Affiliation(s)
- S H Rangwala
- Monsanto Corporate Research, Monsanto Co., St. Louis, MO 63198
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Menéndez-Arias L, Young M, Oroszlan S. Purification and characterization of the mouse mammary tumor virus protease expressed in Escherichia coli. J Biol Chem 1992. [DOI: 10.1016/s0021-9258(18)35956-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
24
|
Hayakawa T, Misumi Y, Kobayashi M, Yamamoto Y, Fujisawa Y. Requirement of N- and C-terminal regions for enzymatic activity of human T-cell leukemia virus type I protease. EUROPEAN JOURNAL OF BIOCHEMISTRY 1992; 206:919-25. [PMID: 1606969 DOI: 10.1111/j.1432-1033.1992.tb17001.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The requirement of N- and C-terminal regions for the enzymatic activity of human T-cell leukemia virus type I (HTLV-I) protease was investigated using a series of deletion mutants. The activity was analyzed by autoprocessing of the protease itself or by processing of the gag p53 precursor. The deletional analyses indicated that Asp38-Gly152 with an additional Met-Pro sequence at the N-terminus was probably sufficient for the enzymatic activity, although the mature HTLV-I protease consists of Pro33-Leu157. A molecular model of HTLV-I protease, which was constructed by comparison with the structure of Rous sarcoma virus protease, predicted that Pro33-Leu37 and Gly143-Leu147 would form a beta-sheet. Our experimental results and the model structure suggest that (a) five amino acids in the N-terminal region (Pro33-Leu37), which are thought to be involved in the beta-sheet, are not crucial for the enzymatic activity; (b) Pro153-Leu157 is not necessary but Pro148-Gly152 is important for the enzymatic activity, in addition to Gly143-Leu147 involved in the beta-sheet.
Collapse
Affiliation(s)
- T Hayakawa
- Biotechnology Research Laboratories, Takeda Chemical Industries Ltd, Osaka, Japan
| | | | | | | | | |
Collapse
|
25
|
Abstract
The human immunodeficiency virus (HIV), the etiological agent for the acquired immune deficiency syndrome (AIDS), is a retrovirus which makes use of a virally-encoded aspartic protease to perform specific proteolytic processing of two of its gene products in order to form active enzymes and structural proteins within the mature virion. Accordingly, specific, exogenous inhibition of the HIV-1 protease is thought to be a viable approach for the development of novel therapeutics for the treatment of AIDS. Indeed, this hypothesis has been validated in virally-infected cell culture with synthetic inhibitors of HIV-1 protease. This chapter reviews the current status of the development of inhibitors of this enzyme.
Collapse
Affiliation(s)
- T D Meek
- Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
| |
Collapse
|
26
|
Affiliation(s)
- J P Snyder
- Drug Design, Searle Research & Development, Skokie, Illinois 60077
| |
Collapse
|
27
|
Louis JM, McDonald RA, Nashed NT, Wondrak EM, Jerina DM, Oroszlan S, Mora PT. Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli. EUROPEAN JOURNAL OF BIOCHEMISTRY 1991; 199:361-9. [PMID: 2070793 DOI: 10.1111/j.1432-1033.1991.tb16132.x] [Citation(s) in RCA: 61] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Various constructs of the human immunodeficiency virus, type 1 (HIV-1) protease containing flanking Pol region sequences were expressed as fusion proteins with the maltose-binding protein of the malE gene of Escherichia coli. The full-length fusion proteins did not exhibit self-processing in E. coli, thereby allowing rapid purification by affinity chromatography on cross-linked amylose columns. Denaturation of the fusion protein in 5 M urea, followed by renaturation, resulted in efficient site-specific autoprocessing to release the 11-kDa protease. Rapid purification involving two column steps gave an HIV-1 protease preparations of greater than 95% purity (specific activity approximately 8500 pmol.min-1.micrograms protease-1) with an overall yield of about 1 mg/l culture. Incubation of an inactive mutant protease fusion protein with the purified wild-type protease resulted in specific trans cleavage and release of the mutant protease. Analysis of products of the HIV-1 fusion proteins containing mutations at either the N- or the C-terminal protease cleavage sites indicated that blocking one of the cleavage sites influences the cleavage at the non-mutated site. Such mutated full-length and truncated protease fusion proteins possess very low levels of proteolytic activity (approximately 5 pmol.min-1.micrograms protein-1).
Collapse
Affiliation(s)
- J M Louis
- Division of Cancer Biology and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | | | | | | | | | | | | |
Collapse
|
28
|
Ross EK, Fuerst TR, Orenstein JM, O'Neill T, Martin MA, Venkatesan S. Maturation of human immunodeficiency virus particles assembled from the gag precursor protein requires in situ processing by gag-pol protease. AIDS Res Hum Retroviruses 1991; 7:475-83. [PMID: 1873082 DOI: 10.1089/aid.1991.7.475] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
The vaccinia virus expression system was used to determine the role of human immunodeficiency virus type 1 (HIV-1) protease in viral morphogenesis and maturation. The unprocessed p55 gag precursor polyprotein alone was assembled to form HIV-1 particles which budded from cells. The particles were spherical and immature, containing an electron-dense shell in the particle submembrane; there was no evidence of core formation. Expression of both gag and pol proteins from a recombinant containing the complete gag-pol coding sequences resulted in intracellular processing of gag-pol proteins and the production of mature particles with electron-dense cores characteristic of wild-type HIV virions. To ascertain the role of protein processing in particle maturation, the pol ORF in the gag-pol recombinant was truncated to limit expression of the pol gene to the protease domain. With this recombinant expressing p55 gag and protease, intracellular processing was observed. Some of the resultant particles were partially mature and contained processed gag protein subunits. In contrast, particle maturation was not observed when the HIV-1 protease and p55 gag were coexpressed from separate recombinants, despite evidence of intracellular gag processing. These findings suggest that HIV-1 protease must be an integral component of the full-length gag-pol precursor for optimal processing and virion maturation.
Collapse
Affiliation(s)
- E K Ross
- Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
| | | | | | | | | | | |
Collapse
|
29
|
Abstract
Specific LexA cleavage can occur under two different conditions: RecA-mediated cleavage requires an activated form of RecA, while an intramolecular self-cleavage termed autodigestion proceeds spontaneously at high pH and does not involve RecA. The two cleavage reactions are closely related. We postulate that RecA stimulates autodigestion rather than acting as a typical protease, and it is proposed to term this activity 'RecA coprotease' to emphasize this indirect role. The mechanism of autodigestion is similar to that of a serine protease, and RecA appears to act by reducing the pKa of a critical lysine residue LexA. A new class of mutants, termed lexA (IndS), is described; these mutations increase the rate of LexA cleavage.
Collapse
Affiliation(s)
- J W Little
- Department of Biochemistry, University of Arizona, Tucson 85721
| |
Collapse
|
30
|
Broadhurst AV, Roberts NA, Ritchie AJ, Handa BK, Kay C. Assay of HIV-1 proteinase: a colorimetric method using small peptide substrates. Anal Biochem 1991; 193:280-6. [PMID: 1872473 DOI: 10.1016/0003-2697(91)90022-l] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
A colorimetric assay for HIV proteinase using small protected peptide substrates is described. Substrates are cleaved to release N-terminal prolyl peptides which react with isatin to form a blue product which is measured spectrophotometrically. The assay is suitable for use with pure enzyme or crude extracts derived from genetically engineered Escherichia coli.
Collapse
Affiliation(s)
- A V Broadhurst
- Department of Chemotherapy Biology, Roche Products Ltd., Welwyn Garden City, Hertfordshire, United Kingdom
| | | | | | | | | |
Collapse
|
31
|
Goobar L, Danielson UH, Brodin P, Grundström T, Oberg B, Norrby E. High-yield purification of HIV-1 proteinase expressed by a synthetic gene in Escherichia coli. Protein Expr Purif 1991; 2:15-23. [PMID: 1821768 DOI: 10.1016/1046-5928(91)90003-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A rapid and simple purification procedure for human immunodeficiency virus type 1 (HIV-1) proteinase from a synthetic gene expressed in Escherichia coli has been developed. The synthetic gene was constructed from oligonucleotides containing several restriction enzyme sites in order to allow simple construction of homologous genes. The protein was translated as a precursor which was autocatalytically processed into the mature protein as shown by N-terminal sequence analysis of the purified protein. Immunoblot analysis was used to verify the nature of the expression product and it was found that 2 of 10 anti-peptide antibodies, covering the whole proteinase sequence, were able to react with the enzyme in crude bacterial lysates. These two anti-peptide antibodies represent a continuous sequence partially overlapping the active site. The purification involves two initial precipitation steps followed by cation-exchange and size-exclusion chromatography. A high yield and a high specific activity were achieved.
Collapse
Affiliation(s)
- L Goobar
- Department of Virology, Karolinska Institute, Stockholm, Sweden
| | | | | | | | | | | |
Collapse
|
32
|
Graves MC. Human immunodeficiency virus proteinase: now, then, what's next? ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1991; 306:395-405. [PMID: 1812736 DOI: 10.1007/978-1-4684-6012-4_52] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- M C Graves
- Department of Molecular Genetics, Roche Research Center, Hoffman-La Roche Inc., Nutley, New Jersey 07110
| |
Collapse
|
33
|
Boutelje J, Karlström AR, Hartmanis MG, Holmgren E, Sjögren A, Levine RL. Human immunodeficiency viral protease is catalytically active as a fusion protein: characterization of the fusion and native enzymes produced in Escherichia coli. Arch Biochem Biophys 1990; 283:141-9. [PMID: 2241167 DOI: 10.1016/0003-9861(90)90624-8] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Processing of the gag and pol gene precursor proteins of retroviruses is essential for the production of mature infectious virions. The processing is directed by a viral protease that itself is part of these precursors and is presumed to cleave itself autocatalytically. To facilitate study of this process, the protease was produced as a fusion protein in Escherichia coli. In this construct, the 10,793-Da protease was preceeded by two copies of a modified IgG binding domain derived from protein A. The IgG binding domain was linked to the protease by an Asp-Pro peptide bond which could not be cleaved by the viral protease. A dimer of the 25,400-Da fusion protein was catalytically active, specifically cleaving a substrate peptide at the correct Tyr-Pro bond. Thus, the fusion protein could serve as a model of the viral gag-pol polyprotein. The finding that the fusion protein was catalytically active supports the suggestion that a gag-pol dimer can initiate a proteolytic cascade after budding of the immature virus. The fusion protein also provided a source of authentic protease. The protease was released from the fusion construct by incubation with formic acid, cleaving the Asp-Pro linkage which had been inserted between the IgG binding domain and the protease.
Collapse
Affiliation(s)
- J Boutelje
- Laboratory of Biochemistry, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892
| | | | | | | | | | | |
Collapse
|
34
|
Lukacsovich T, Orosz A, Baliko G, Venetianer P. A family of expression vectors based on the rrnBP2 promoter of Escherichia coli. J Biotechnol 1990; 16:49-55. [PMID: 1370011 DOI: 10.1016/0168-1656(90)90064-i] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
We describe here the construction of a family of expression vectors, based on the P2 promoter of the Escherichia coli rrnB gene by removing regulatory sequences downstream of the Pribnow-box and replacing them with the lac operator. These vectors allow cloning of foreign genes in such a way that their products are synthesized either in the form of fusion proteins of different length, or without fusion partners, with or without the original translational initiation signals. One of the vectors contains a synthetic oligothreonine-coding sequence that helps to stabilize the product of the cloned gene. These vectors allow high-level regulated expression of foreign genes, even if their products are relatively short peptides.
Collapse
Affiliation(s)
- T Lukacsovich
- Institute of Biochemistry, Biological Research Center of the Hungarian Academy of Sciences, Szeged
| | | | | | | |
Collapse
|
35
|
Abstract
Pepstatin A, a pentapeptide aspartyl protease inhibitor, can spontaneously polymerize into filaments having a helical substructure and, after negative staining, characteristic diameters ranging from 6 to 12 nm. Optical diffraction analysis demonstrated that these filaments consist of a 6-nm-wide strand helically wound with a periodic pitch of 25 nm. Selected images suggest that these filaments may actually be composed of two, intertwined 6-nm-wide strands, an hypothesis not at variance with the diffraction data. These filaments may extend over several micrometers. At low ionic strength and neutral pH, the critical concentration for pepstatin A filament assembly is 0.1 mM. At higher pepstatin A concentrations or in physiological salt solutions, a variety of higher order structures were observed, including ribbons, sheets, and cylinders with both regular and twisted or irregular geometries. Pepstatin A polymerized into these higher order structures loses its ability to inhibit the aspartyl protease of the human immunodeficiency virus type 1. These results have implications not only for model studies on the polymerization of small peptides into higher order structures, but also for the practical development of soluble protease inhibitors.
Collapse
Affiliation(s)
- E Mothes
- Max-Planck-Institut für Zellbiologie, Ladenburg/Heidelberg, Federal Republic of Germany
| | | | | | | |
Collapse
|
36
|
DiIanni CL, Davis LJ, Holloway MK, Herber WK, Darke PL, Kohl NE, Dixon RA. Characterization of an active single polypeptide form of the human immunodeficiency virus type 1 protease. J Biol Chem 1990. [DOI: 10.1016/s0021-9258(17)44909-x] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
37
|
Rittenhouse J, Turon MC, Helfrich RJ, Albrecht KS, Weigl D, Simmer RL, Mordini F, Erickson J, Kohlbrenner WE. Affinity purification of HIV-1 and HIV-2 proteases from recombinant E. coli strains using pepstatin-agarose. Biochem Biophys Res Commun 1990; 171:60-6. [PMID: 2203350 DOI: 10.1016/0006-291x(90)91356-w] [Citation(s) in RCA: 32] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A procedure is described which employs pepstatin-agarose for the affinity purification of either HIV-1 or HIV-2 protease from two similar recombinant E. coli constructs that were developed for the expression of these enzymes. HIV-2 protease was routinely expressed at much higher levels than the HIV-1 enzyme and pepstatin-agarose was the only chromatography step required to isolate pure HIV-2 protease from crude bacterial lysates. A Mono S ionic exchange step following pepstatin-agarose chromatography was sufficient to bring the HIV-1 protease to homogeneity. Purification of either enzyme can be completed in several days yielding homogeneous preparations suitable for crystallization and other physical characterization.
Collapse
Affiliation(s)
- J Rittenhouse
- Pharmaceutical Products Division, Abbott Laboratories, IL 60064-3500
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Pichuantes S, Babé L, Barr P, DeCamp D, Craik C. Recombinant HIV2 protease processes HIV1 Pr53gag and analogous junction peptides in vitro. J Biol Chem 1990. [DOI: 10.1016/s0021-9258(18)77432-2] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
39
|
Tomasselli A, Hui J, Sawyer T, Staples D, Bannow C, Reardon I, Howe W, DeCamp D, Craik C, Heinrikson R. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J Biol Chem 1990. [DOI: 10.1016/s0021-9258(18)77355-9] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
40
|
Pistillo JM, Vishwanatha JK. Expression of simian virus 40 large T antigen in Escherichia coli using vectors based on the regulatable rac promoter. Biochem Biophys Res Commun 1990; 169:1129-37. [PMID: 2194454 DOI: 10.1016/0006-291x(90)92013-p] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Simian Virus 40 large T antigen is a multi-functional protein that is involved in the initiation of viral DNA replication, regulation of viral transcription and cell transformation. Bacterial expression vectors, pER23-1 and pER23-2, that are based on the regulatable rac promoter were used to produce T antigen either as a free protein or as a fusion protein. We have observed efficient transcription of the cloned T antigen gene in most of the recombinants. However, expression of the T antigen protein was inefficient and most of the expressed protein was truncated. This may be due to differences in codon usage in E. coli or to rapid protein degradation.
Collapse
Affiliation(s)
- J M Pistillo
- Department of Biochemistry, University of Nebraska Medical Center, Omaha 68198-4525
| | | |
Collapse
|
41
|
Rockenbach SK, Olsen MK, Tomich CS. A simple Escherichia coli system for monitoring HIV protease activity: analysis of two temperature-sensitive protease mutants. AIDS Res Hum Retroviruses 1990; 6:543-52. [PMID: 2187504 DOI: 10.1089/aid.1990.6.543] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
A simple Escherichia coli system has been developed for the detection of human immunodeficiency virus (HIV) protease activity. In this system, the protease sequence is placed downstream of the HIV gag polypeptide in an operon arrangement. Upon expression of the operon, gag serves as the substrate for the protease; the level of protease activity can be determined by measurement of the cleavage product of gag in cell extracts by Western immunoblotting. This system is useful in both detection of protease mutations generated by mutagenesis and in testing substrate specificity of the protease by mutagenesis of the gag sequence. Using this system, we have observed that modification of the N-terminus of HIV protease renders the enzyme temperature sensitive; the temperature sensitivity is made more pronounced by the conserved change of valine to isoleucine at residue eleven.
Collapse
Affiliation(s)
- S K Rockenbach
- Molecular Biology Research, Upjohn Company, Kalamazoo, MI 49001
| | | | | |
Collapse
|
42
|
Cheng YS, McGowan MH, Kettner CA, Schloss JV, Erickson-Viitanen S, Yin FH. High-level synthesis of recombinant HIV-1 protease and the recovery of active enzyme from inclusion bodies. Gene 1990; 87:243-8. [PMID: 2158928 DOI: 10.1016/0378-1119(90)90308-e] [Citation(s) in RCA: 54] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A complete chemical synthesis and assembly of genes for the production of human immunodeficiency virus type-I protease (HIV-PR) and its precursors are described. The T7 expression system was used to produce high levels of active HIV-PR and its precursors in Escherichia coli inclusion bodies. The gene encoding the open reading frames of HIV-PR was expressed in E. coli as a 10-kDa protein, while the genes encoding HIV-PR precursors were expressed as larger proteins, which were partially processed in E. coli to the 10-kDa form. These processing events are autoproteolytic, since a single-base mutation, changing the active-site aspartic acid to glycine, completely abolished the conversion. HIV-PR can be released with 8 M urea from washed cellular inclusion bodies, resulting in a preparation with few bacterial host proteins. After refolding, this preparation contains no nonspecific protease or peptidase activities. The recombinant HIV-PR isolated from inclusion bodies cleaves HIV-PR substrates specifically with a specific activity comparable to column-purified HIV-PR.
Collapse
Affiliation(s)
- Y S Cheng
- Central Research and Development Department, E.I. duPont de Nemours and Co., Wilmington, DE 19880-0328
| | | | | | | | | | | |
Collapse
|
43
|
Lukacsovich T, Baliko G, Orosz A, Balla E, Venetianer P. New approaches to increase the expression and stability of cloned foreign genes in Escherichia coli. J Biotechnol 1990; 13:243-50. [PMID: 1366558 DOI: 10.1016/0168-1656(90)90072-j] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
A family of expression plasmid vectors were constructed by fusing the strong P2 promoter of the rrnB gene of Escherichia coli (coding for ribosomal RNA) to the lac operator, thereby eliminating regulatory sequences from the rrnB gene and placing the expression under lac repressor control. This promoter proved to be stronger in vivo than the well-known consensus tac promoter, and its strength could be further increased by converting the sequence to consensus. The stability of the recombinant proteins could be increased by fusion to various lengths of the N-terminal end of beta-galactosidase, or by inserting a synthetic oligonucleotide, coding for heptathreonine. A new method was developed for the stabilization of recombinant plasmids without antibiotic selection, based on the presence of an essential gene on the plasmid and its absence from the chromosome. The application of this method is illustrated by the example of a plasmid expressing human proinsulin.
Collapse
Affiliation(s)
- T Lukacsovich
- Institute of Biochemistry, Biological Research Center of the Hungarian Academy of Sciences, Szeged, Hungary
| | | | | | | | | |
Collapse
|
44
|
Matayoshi ED, Wang GT, Krafft GA, Erickson J. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 1990; 247:954-8. [PMID: 2106161 DOI: 10.1126/science.2106161] [Citation(s) in RCA: 495] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The 11-kD protease (PR) encoded by the human immunodeficiency virus 1 (HIV-1) is essential for the correct processing of viral polyproteins and the maturation of infectious virus, and is therefore a target for the design of selective acquired immunodeficiency syndrome (AIDS) therapeutics. To facilitate the identification of novel inhibitors of HIV-1 PR, as well as to permit detailed studies on the enzymology and inhibition of this enzyme, a continuous assay for its activity was developed that was based on intramolecular fluorescence resonance energy transfer (RET). The assay used the quenched fluorogenic substrate 4-(4-dimethylaminophenylazo)benzoic acid (DABCYL)--Ser Gln Asn Tyr Pro Ile Val Gln--5-[(2-aminoethyl)amino]naphthalene-1 sulfonic acid (EDANS), whose peptide sequence is derived from a natural processing site for HIV-1 PR. Incubation of recombinant HIV-1 PR with the fluorogenic substrate resulted in specific cleavage at the Tyr-Pro bond and a time-dependent increase in fluorescence intensity that was linearly related to the extent of substrate hydrolysis. An internally quenched fluorogenic substrate was also designed that was selectively cleaved by the related PR from avian myeloblastosis virus (AMV). The fluorescence quantum yields of the HIV-1 PR and AMV PR substrates in the RET assay increased by 40.0- and 34.4-fold, respectively, per mole of substrate cleaved. Because of its simplicity, rapidity, and precision in the determination of reaction rates required for kinetic analysis, this method offers many advantages over the commonly used high-performance liquid chromatography- or electrophoresis-based assays for peptide substrate hydrolysis by retroviral PRs.
Collapse
Affiliation(s)
- E D Matayoshi
- Pharmaceutical Discovery Division, Abbott Laboratories, Abbott Park, IL 60064
| | | | | | | |
Collapse
|
45
|
Tomasselli AG, Olsen MK, Hui JO, Staples DJ, Sawyer TK, Heinrikson RL, Tomich CS. Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease. Biochemistry 1990; 29:264-9. [PMID: 2182116 DOI: 10.1021/bi00453a036] [Citation(s) in RCA: 106] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The aspartyl protease of human immunodeficiency virus 1 (HIV-1) has been expressed in Escherichia coli at high levels, resulting in the formation of inclusion bodies which contain denatured insoluble aggregates of the protease. After solubilization of these inclusion bodies in guanidinium chloride, the protease was purified to apparent homogeneity by a single-step reverse-phase HPLC procedure. The purified, but inactive, protein was denatured in 8 M urea and refolded to produce the active protease. Enzyme activity was demonstrated against the substrate H-Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val-OH, modeled after the cleavage region between residues 128 and 135 in the HIV gag polyprotein. With this substrate, a Vmax of 1.3 +/- 0.2 mumol/(min.mg) and KM of 2.0 +/- 0.3 mM were determined at pH 5.5. Pepstatin (Iva-Val-Val-Sta-Ala-Sta-OH) and substrate analogues with the Tyr-Pro residues substituted by Sta, by Phe psi [CH2N]Pro, and by Leu psi [CH(OH)CH2]Val inhibited the protease with KI values of 360 nM, 3690 nM, 3520 nM, and less than 10 nM, respectively. All were competitive inhibitors, and the tightest binding compound provided an active site titrant for the quantitative determination of enzymatically active HIV-1 protease.
Collapse
Affiliation(s)
- A G Tomasselli
- Biopolymer Chemistry, Research Unit, Upjohn Company, Kalamazoo, Michigan 49001
| | | | | | | | | | | | | |
Collapse
|
46
|
Wang GT, Matayoshi E, Jan Huffaker H, Krafft GA. Design and synthesis of new fluorogenic HIV protease substrates based on resonance energy transfer. Tetrahedron Lett 1990. [DOI: 10.1016/s0040-4039(00)97099-0] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
Kaderbhai MA, He MY, Beechey RB, Kaderbhai N. Co-expression of a precursor and the mature protein of wheat ribulose-1,5-bisphosphate carboxylase small subunit from a single gene in Escherichia coli. DNA Cell Biol 1990; 9:11-25. [PMID: 2180428 DOI: 10.1089/dna.1990.9.11] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
The cDNA encoding a precursor of wheat ribulose-1,5-bisphosphate carboxylase/oxygenase was inserted in-phase with prokaryotic expression elements in four different vectors. Five expression vectors encoding the small subunit precursors were cloned in Escherichia coli. None of these constructs expressed detectable amounts of the precursor protein, but all directed synthesis of the mature small subunit. The expression of the small subunit was a consequence of an independent, intragenic Shine-Dalgarno sequence optimally located upstream from an ATG specifying the first codon of the mature small subunit portion in the precursor transcript. Similar internal translation signals have been identified in the nuclear-encoded cDNAs of the small-subunit precursors of numerous higher plant genes. The 5' end of the wheat small-subunit precursor was linked with a consensus E. coli DNA sequence such that the modified gene encoded a partial hybrid precursor carrying four additional residues at its amino terminus. The resultant construct, pEI-W3, directed abundant synthesis of both the partially hybrid small-subunit precursor and the mature small subunit, constituting as much as 10% of the total bacterial protein. The bacterially synthesized small subunit precursor was purified to homogeneity. The authenticity of the recombinant protein was verified by its size, immunological properties, amino-terminal sequence, and amino acid composition.
Collapse
Affiliation(s)
- M A Kaderbhai
- Department of Biochemistry, University College of Wales, Aberystwyth, Dyfed, UK
| | | | | | | |
Collapse
|
48
|
BILLICH A, HAMMERSCHMID F, WINKLER G. Purification, Assay and Kinetic Features of HIV-1 Proteinase. ACTA ACUST UNITED AC 1990. [DOI: 10.1515/bchm3.1990.371.1.265] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
49
|
Interdomain hydrolysis of a truncated Pseudomonas exotoxin by the human immunodeficiency virus-1 protease. J Biol Chem 1990. [DOI: 10.1016/s0021-9258(19)40245-7] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
50
|
Debouck C, Metcalf BW. Human immunodeficiency virus protease: A target for aids therapy. Drug Dev Res 1990. [DOI: 10.1002/ddr.430210102] [Citation(s) in RCA: 64] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|